Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-OUTCOMES
2023-508630-34-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- Peptides
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity, atherosclerotic disease and 1 more comparing Retatrutide once weekly with Placebo once weekly (2 arms). Primary endpoints: Time to first occurrence of composite major adverse cardiovascular endpoint and Time to first occurrence of composite major adverse kidney endpoint. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
Overweightobesityatherosclerotic diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-508630-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508630-34-00.